AC Immune SA - ADR

Name: AC Immune SA - ADR Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: AC Immune SA - ADR

Stock Card

$2.65

$-0.06 (-2.21%)

As on 28-Aug-2026 16:00EDT

Market cap

$263 Mln

Revenue (TTM)

$18 Mln

P/E Ratio

P/B Ratio

6.1

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

AC Immune SA - ADR Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 2.65 High: 2.77

52 Week Range

Low: 2.03 High: 4.00

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.8 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.8
Debt to Equity

0
Book Value

$0.4
EPS

$-0.4
Face value

--
Shares outstanding

99,426,932

10 Years Aggregate

CFO

CHF-249.32 Mln

EBITDA

CHF-249.04 Mln

Net Profit

CHF-268.09 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
AC Immune SA - ADR	-15.6	15.2	-9.6	28.0	-4.7	-17.5	--
BSE Sensex^*	-9.1	-1.2	2.9	-3.6	5.7	6.2	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | *As on 31-Aug-2026 | #As on 26-Oct-2023

Company	2025	2023	2022	2021	2020	2019
AC Immune SA - ADR	16.3	145.1	-58.8	-4.3	-39.3	-9.8
S&P Small-Cap 600	4.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About AC Immune SA - ADR

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The... company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland. Read more

Co-Founder, CEO & Director

Dr. Andrea Pfeifer Ph.D.
Co-Founder, CEO & Director

Dr. Andrea Pfeifer Ph.D.
Headquarters

Lausanne
Website

https://www.acimmune.com

FAQs for AC Immune SA - ADR

What is the current share price of AC Immune SA - ADR Today?

The share price of AC Immune SA - ADR is $2.65 (NASDAQ) as of 28-Aug-2026 16:00 EDT. AC Immune SA - ADR has given a return of -4.68% in the last 3 years.

What is the current PB & PE ratio of AC Immune SA - ADR?

Since, TTM earnings of AC Immune SA - ADR is negative, P/E ratio is not available.
The P/B ratio of AC Immune SA - ADR is 6.14 times as on 28-Aug-2026, a 138 premium to its peers’ median range of 2.58 times.

PE & PB ratio at the end of financial year.